BIND Therapeutics to Report First Quarter 2015 Financial Results on May 7, 2015

CAMBRIDGE, Mass.--()--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced it will host a conference call and live audio webcast on May 7, 2015, at 8:30 a.m. ET to report first quarter 2015 financial results.

To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 32368364. A live audio webcast of the call will also be available on the Investors & Media section of the Company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company’s website approximately two hours after the event.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins™, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd. and Merck (known as Merck Sharp & Dohme outside the United States and Canada) to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. For more information, please visit the Company's website at www.bindtherapeutics.com.

Contacts

BIND Therapeutics, Inc.
Media:
Jeff Boyle, 347-247-5089
media@bindtherapeutics.com
or
Investors:
Tom Baker, 617-532-0624
investors@bindtherapeutics.com

BIND Therapeutics, Inc.